ITH12410/SC058: A new neuroprotective compound with potential in the treatment of Alzheimer's disease

ACS Chemical Neuroscience

Volumn 5, Issue 9, 2014, Pages 770-775

  Romero, Alejandro ^a,d   Egea, Javier ^a   Gonzaléz Muñoz, Gema C ^c   De Saavedra, Ma Dolores Martín ^a,e   Barrio, Laura Del ^a,f   Rodríguez Franco, María Isabel ^c   Conde, Santiago ^c   López, Manuela G ^a,b   Villarroya, Mercedes ^a   De Ríos, Cristóbal Los ^a,b  

^a INSTITUTO TEÓFILO HERNANDO   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^e NORTHWESTERN UNIVERSITY   (United States)

^f ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Alzheimer's disease; Amyloid beta; Dibenzothiadiazepine; Neurodegenerative diseases; Neurofibrillary tangles; Neuroprotective drugs; Oxidative stress

Indexed keywords

2 CHLORO 5,6 DIHYDRO 5,6 DIACETYLDIBENZO[ B F][1,4,5]THIADIAZEPINE; AMYLOID BETA PROTEIN; CALCIUM; DIAZEPINE DERIVATIVE; NOOTROPIC AGENT; OKADAIC ACID; OLIGOMYCIN; PHOSPHOPROTEIN PHOSPHATASE 2A; ROTENONE; UNCLASSIFIED DRUG; 2-CHLORO-5,6-DIHYDRO-5,6-DIACETYLDIBENZO(B,F)(1,4,5)THIADIAZEPINE; DIBENZOTHIAZEPINE DERIVATIVE; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REOXYGENATION; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; DRUG EFFECTS;

RATTUS;

ALZHEIMER DISEASE; ANIMALS; DIBENZOTHIAZEPINES; HUMANS; MODELS, BIOLOGICAL; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS;

EID: 84907971165     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn500131t     Document Type: Article

References (34)

1. Carreiras, M. C., Mendes, E., Perry, M. J., Francisco, A. P., and Marco-Contelles, J. (2013) The multifactorial nature of Alzheimer's disease for developing potential therapeutics. Curr. Top. Med. Chem. 13, 1745-1770.
2. Cavalli, A., Bolognesi, M. L., Capsoni, S., Andrisano, V., Bartolini, M., Margotti, E., Cattaneo, A., Recanatini, M., and Melchiorre, C. (2007) A small molecule targeting the multifactorial nature of Alzheimer's disease. Angew. Chem., Int. Ed. Engl. 46, 3689-3692.
3. Rodriguez-Franco, M. I., Fernandez-Bachiller, M. I., Perez, C., Hernandez-Ledesma, B., and Bartolome, B. (2006) Novel tacrine-melatonin hybrids as dual-acting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. J. Med. Chem. 49, 459-462.
4. Leon, R., and Marco-Contelles, J. (2011) A step further towards multitarget drugs for Alzheimer and neuronal vascular diseases: targeting the cholinergic system, amyloid-beta aggregation and Ca2+ dyshomeostasis. Curr. Med. Chem. 18, 552-576.
5. Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., and Melchiorre, C. (2008) Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem. 51, 347-372.
6. Espinoza-Fonseca, L. M. (2006) The benefits of the multi-target approach in drug design and discovery. Bioorg. Med. Chem. 14, 896-897.
7. Arce, M. P., Rodriguez-Franco, M. I., Gonzalez-Munoz, G. C., Perez, C., Lopez, B., Villarroya, M., Lopez, M. G., Garcia, A. G., and Conde, S. (2009) Neuroprotective and cholinergic properties of multifunctional glutamic acid derivatives for the treatment of Alzheimer's disease. J. Med. Chem. 52, 7249-7257.
8. Lorrio, S., Romero, A., Gonzalez-Lafuente, L., Lajarin-Cuesta, R., Martinez-Sanz, F. J., Estrada, M., Samadi, A., Marco-Contelles, J., Rodriguez-Franco, M. I., Villarroya, M., Lopez, M. G., and de los Rios, C. (2013) PP2A ligand ITH12246 protects against memory impairment and focal cerebral ischemia in mice. ACS Chem. Neurosci. 4, 1267-1277.
9. Butterfield, D. A., Reed, T., Newman, S. F., and Sultana, R. (2007) Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radical Biol. Med. 43, 658-677.
10. Fernandez-Morales, J. C., Arranz-Tagarro, J. A., Calvo-Gallardo, E., Maroto, M., Padin, J. F., and Garcia, A. G. (2012) Stabilizers of neuronal and mitochondrial calcium cycling as a strategy for developing a medicine for Alzheimer's disease. ACS Chem. Neurosci. 3, 873-883.
11. Barger, S. W., Horster, D., Furukawa, K., Goodman, Y., Krieglstein, J., and Mattson, M. P. (1995) Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc. Natl. Acad. Sci. U.S.A. 92, 9328-9332.
12. Huang, H. M., Ou, H. C., and Hsieh, S. J. (2000) Antioxidants prevent amyloid peptide-induced apoptosis and alteration of calcium homeostasis in cultured cortical neurons. Life Sci. 66, 1879-1892.
13. Gonzalez-Munoz, G. C., Arce, M. P., Lopez, B., Perez, C., Romero, A., del Barrio, L., Martin-de-Saavedra, M. D., Egea, J., Leon, R., Villarroya, M., Lopez, M. G., Garcia, A. G., Conde, S., and Rodriguez-Franco, M. I. (2011) N-acylaminophenothiazines: neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease. Eur. J. Med. Chem. 46, 2224-2235.
14. González-Muñoz, G. C., Arce, M. P., Perez, C., Romero, A., Villarroya, M., López, M. G., Conde, S., and Rodríguez-Franco, M. I. (2014) Dibenzo[1,4,5]thiadiazepine: a hardly-known heterocyclic system with neuroprotective properties of potential usefulness in the treatment of neurodegenerative disease. Eur. J. Med. Chem. 81, 350-358.
15. Corral, C., Lissavetzky, J., and Quintanilla, G. (1982) New method for the synthesis of chloro-substituted dibenzo[b,f ][1,4,5]-thiadiazepines and their 5,6-dihydro derivatives. J. Org. Chem. 47, 2214-2215.
16. Egea, J., Rosa, A. O., Cuadrado, A., Garcia, A. G., and Lopez, M. G. (2007) Nicotinic receptor activation by epibatidine induces heme oxygenase-1 and protects chromaffin cells against oxidative stress. J. Neurochem. 102, 1842-1852.
17. Denizot, F., and Lang, R. (1986) Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods 89, 271-277.
18. Egea, J., Rosa, A. O., Sobrado, M., Gandia, L., Lopez, M. G., and Garcia, A. G. (2007) Neuroprotection afforded by nicotine against oxygen and glucose deprivation in hippocampal slices is lost in alpha7 nicotinic receptor knockout mice. Neuroscience 145, 866-872.
19. De Lacoste, M. C., and White, C. L., 3rd. (1993) The role of cortical connectivity in Alzheimer's disease pathogenesis: a review and model system. Neurobiol. Aging 14, 1-16.
20. Hensley, K., Carney, J. M., Mattson, M. P., Aksenova, M., Harris, M., Wu, J. F., Floyd, R. A., and Butterfield, D. A. (1994) A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 91, 3270-3274.
21. Masilamoni, J. G., Jesudason, E. P., Dhandayuthapani, S., Ashok, B. S., Vignesh, S., Jebaraj, W. C., Paul, S. F., and Jayakumar, R. (2008) The neuroprotective role of melatonin against amyloid beta peptide injected mice. Free Radical Res. 42, 661-673.
22. Younkin, S. G. (1998) The role of A beta 42 in Alzheimer's disease. J. Physiol. (Paris) 92, 289-292.
23. Selkoe, D. J. (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741-766.
24. Mayeux, R., Honig, L. S., Tang, M. X., Manly, J., Stern, Y., Schupf, N., and Mehta, P. D. (2003) Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 61, 1185-1190.
25. Gandhi, S., Wood-Kaczmar, A., Yao, Z., Plun-Favreau, H., Deas, E., Klupsch, K., Downward, J., Latchman, D. S., Tabrizi, S. J., Wood, N. W., Duchen, M. R., and Abramov, A. Y. (2009) PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. Mol. Cell 33, 627-638.
26. Zheng, W., Rampe, D., and Triggle, D. J. (1991) Pharmacological, radioligand binding, and electrophysiological characteristics of FPL 64176, a novel nondihydropyridine Ca2+ channel activator, in cardiac and vascular preparations. Mol. Pharmacol. 40, 734-741.
27. Cano-Abad, M. F., Villarroya, M., Garcia, A. G., Gabilan, N. H., and Lopez, M. G. (2001) Calcium entry through L-type calcium channels causes mitochondrial disruption and chromaffin cell death. J. Biol. Chem. 276, 39695-39704.
28. Iqbal, K., and Grundke-Iqbal, I. (2005) Pharmacological approaches of neurofibrillary degeneration. Curr. Alzheimer Res. 2, 335-341.
29. Liu, F., Grundke-Iqbal, I., Iqbal, K., and Gong, C. X. (2005) Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur. J. Neurosci. 22, 1942-1950.
30. Medina, M., Avila, J., and Villanueva, N. (2013) Use of okadaic acid to identify relevant phosphoepitopes in pathology: A focus on neurodegeneration. Mar. Drugs 11, 1656-1668.
31. Tian, Q., Lin, Z. Q., Wang, X. C., Chen, J., Wang, Q., Gong, C. X., and Wang, J. Z. (2004) Injection of okadaic acid into the meynert nucleus basalis of rat brain induces decreased acetylcholine level and spatial memory deficit. Neuroscience 126, 277-284.
32. Uberti, D., Rizzini, C., Spano, P. F., and Memo, M. (1997) Characterization of tau proteins in human neuroblastoma SH-SY5Y cell line. Neurosci. Lett. 235, 149-153.
33. de Los Rios, C., Egea, J., Marco-Contelles, J., Leon, R., Samadi, A., Iriepa, I., Moraleda, I., Galvez, E., Garcia, A. G., Lopez, M. G., Villarroya, M., and Romero, A. (2010) Synthesis, inhibitory activity of cholinesterases, and neuroprotective profile of novel 1,8-naphthyridine derivatives. J. Med. Chem. 53, 5129-5143.
34. Bolognesi, M. L., Matera, R., Minarini, A., Rosini, M., and Melchiorre, C. (2009) Alzheimer's disease: New approaches to drug discovery. Curr. Opin. Chem. Biol. 13, 303-308.